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ABSTRACT
Introduction: Relationships between exacerbations of
chronic obstructive pulmonary disease (COPD) and
environmental factors such as temperature, humidity
and air pollution are not well characterised, due in part
to oversimplification in the assignment of exposure
estimates to individuals and populations. New
developments in miniature environmental sensors
mean that patients can now carry a personal air quality
monitor for long periods of time as they go about their
daily lives. This creates the potential for capturing a
direct link between individual activities, environmental
exposures and the health of patients with COPD. Direct
associations then have the potential to be scaled up to
population levels and tested using advanced human
exposure models linked to electronic health records.
Methods and analysis: This study has 5 stages: (1)
development and deployment of personal air monitors;
(2) recruitment and monitoring of a cohort of 160
patients with COPD for up to 6 months with
recruitment of participants through the Clinical Practice
Research Datalink (CPRD); (3) statistical associations
between personal exposure with COPD-related health
outcomes; (4) validation of a time-activity exposure
model and (5) development of a COPD prediction
model for London.
Ethics and dissemination: The Research Ethics
Committee for Camden and Islington has provided
ethical approval for the conduct of the study. Approval
has also been granted by National Health Service
(NHS) Research and Development and the Independent
Scientific Advisory Committee. The results of the study
will be disseminated through appropriate conference
presentations and peer-reviewed journals.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is a chronic progressive disease asso-
ciated with the abnormal inﬂammatory
response of the lungs to noxious particles or
gases1 and is characterised by increased resist-
ance to airﬂow in small conducting airways,
changes in lung compliance and the prema-
ture collapse of airways during expiration.2
The inﬂammatory responses can lead to
increased sputum production, breathlessness
and reduced lung function, often resulting in
reduced exercise tolerance and decreased
quality of life.3 4 COPD has a large burden on
healthcare resources with an estimated annual
cost to the National Health Service (NHS) cur-
rently of over £800 million.5 At present, it is
Strengths and limitations of this study
▪ This study will allow researchers to assess asso-
ciations in far more detail, initially at the individ-
ual patient level and potentially at a national
level.
▪ It will demonstrate the integration of novel meth-
odological approaches in three main areas: (1)
the recruitment of participants via an anon-
ymised general practice records database, and
use of electronic health records to gather infor-
mation on chronic obstructive pulmonary
disease (COPD) exacerbations; (2) mass deploy-
ment of portable air quality sensor platforms
over long periods revolutionising the way in
which personal exposure can be quantified and
(3) the application of a dynamic human exposure
model.
▪ Much of the success depends on participant par-
ticipation over a long period (up to 6 months)
and there may be difficulties with recruiting
enough participants to power the study.
▪ Physiological and inflammatory changes are not
being recorded as part of this study; however,
these issues will be addressed in this protocol
and will be examined in a substudy of character-
isation of COPD exacerbations using environ-
mental exposure modelling.
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the fourth leading cause of death worldwide, and it is pre-
dicted that total deaths from COPD may increase by more
than 30% in the next 10 years unless urgent action is
taken to reduce the underlying risk factors.6
Smoking is the most important risk factor for COPD;
however, an estimated 25–45% of patients have never
smoked. Other risk factors include a history of pulmon-
ary tuberculosis, chronic asthma, childhood respiratory
tract infections, occupational exposure to dusts and
gases, air pollution and low socioeconomic status.7 The
prevalence of COPD is increased in individuals living
close to trafﬁc,8 and patients with COPD have substantial
mortality risks associated with particles9 and temperature
changes.10–12 Exacerbations of COPD are acute episodes
of deterioration associated with increased mortality and
decreased quality of life, and are the second most
common cause of adult emergency medical hospital
admission in the UK.8 Infections, both bacterial and
viral, are known to play a major role in exacerbations.4
Gaps still exist in our understanding of the mechanisms
involved in exacerbations and the particular air pollu-
tants and environmental conditions that lead to
increased hospitalisations. Previous systematic reviews
and meta-analytic studies have found small but signiﬁcant
effects of particulate matter (PM10 and PM2.5) and gases
such as ozone (O3) and nitrogen dioxide (NO2) on
COPD-related admissions and mortality.13–17 However,
such ﬁndings are only indicative, as the evidence comes
from a relatively small number of time-series and case-
crossover studies with signiﬁcant heterogeneity between
them. The methodological design of those studies intro-
duced additional limitations in the interpretability of the
ﬁndings stemming from the inability to accurately charac-
terise exposure to air pollutants at the individual level.
Such critical limitations have been the absence in most
studies of detailed activity patterns, the reliance on aggre-
gated health counts and the low spatiotemporal reso-
lution of air pollution from a small number of ﬁxed
monitoring sites resulting in the inadequate adjustment
for confounders and covariance between air pollutants.
Consequently, there has been a continued effort to
understand the relationship between ambient concentra-
tions and personal exposure. Personal exposure assess-
ment requires the recording of a person’s time-activity
patterns, as well as the pollutant concentrations which
each individual is exposed to. At the most basic level,
this may be the relative proportion of time spent in dif-
ferent microenvironments. Additionally, activity type of
individuals may affect indoor air pollution levels, while
activity levels may alter dose. Estimating personal expos-
ure has been challenging, because of the expense and
availability of personal monitors, as well as the lack of
detailed information at the individual level which is
limited by the accuracy of time-activity diaries, which can
be laborious, introduce recall biases and reliability, and
require active cooperation of the participants in the
monitoring process, often limiting their application in
small panel studies.
This research is timely as it brings together recent
advancements in technological aspects of personal air
quality monitors and computational developments to
create detailed hybrid models of personal exposure.
This paper presents the integrated methodological
framework which will be used for the ‘characterisation
of COPD exacerbations using environmental exposure
modelling’ (COPE) study. This research project takes
the ﬁrst steps towards the integration of novel methodo-
logical approaches in three main areas : (1) the recruit-
ment of participants via an anonymised general practice
records database, and use of primary care electronic
records to gather information on COPD exacerbations;
(2) mass deployment of portable air quality sensor plat-
forms over long periods revolutionising the way in which
personal exposure can be quantiﬁed with automated
classiﬁcation of individual time-activity patterns and
exposure events and (3) the application of a dynamic
human exposure model. Together, these have the poten-
tial to provide powerful tools to create and validate
accurate personal exposure models with higher spatio-
temporal resolution, allowing, for the ﬁrst time, the
incorporation of spatially realistic exposure models in
epidemiological studies.
METHODS AND ANALYSIS
A series of ﬁve work packages move through a number
of phases, from instrument development and recruit-
ment, through cohort monitoring and analysis, to pre-
dictive model development (ﬁgure 1).
Development and long-term deployment of personal air
pollution sensors
Personal air monitors (PAMs) have been designed, manu-
factured and tested speciﬁcally for the COPE study
(ﬁgure 2). The PAMs can be either strapped around the
waist with a belt or worn over the shoulder. A waterproof
case will be provided to the participants to make it less
conspicuous when worn outside the house. The PAMs
will employ ubiquitous sensing of a large number of geo-
temporal environmental parameters that can be mea-
sured simultaneously (table 1). The measurements will
be stored in the sensor and uploaded through General
Packet Radio Service to a secure server through the char-
ging base station. No interaction with the unit is required
by the participant, other than to place it in its charger
each night (the battery life of the sensor is 30 hours
between charges). It will operate continuously and is
almost silent.
In order to reduce transmission costs and the compu-
tational burden of the portable device, transmitted data
from the accelerometer and microphone will be
reduced by event counting within 20 s non-overlapping
windows. Spatial points resulting from Global
Positioning System (GPS) coordinate errors were identi-
ﬁed and have been removed based on Euclidean dis-
tance and earth bearing between consecutive points.
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The selected gases (NO2, O3, NO and CO) will be
quantiﬁed with electrochemical sensors based on
amperometric methods at parts-per-billion (ppb)
mixing ratios. Once appropriate calibration factors and
postprocessing have been applied to sensor data, excel-
lent sensitivity can be achieved in laboratory and ﬁeld
settings.18 The PAM incorporates a miniaturised optical
particle counter that will record particle counts in 16
particle sizes (bins) in the range from 0.35 to >17 μm.
The bins will then be aggregated to estimate the mass of
the three fractions PM1, PM2.5 and PM10.
Participant recruitment and monitoring
Recruitment of panel participants
Traditionally, recruitment for observational studies
involves time-consuming and labour-intensive contact
with suitable participants that meet the inclusion/exclu-
sion criteria. In this study, we employ a novel method of
recruitment that involves approaching GPs and patients
to participate through the Clinical Practice Research
Datalink (CPRD), an anonymised general practice
records database containing ongoing primary care
medical data. This method of recruiting for observa-
tional and interventional studies has been shown to be
effective in a pharmacogenetic study;19 and in a cluster
randomised control trial on asthma exacerbation among
school-aged children.20 Apart from the efﬁciency in
recruiting participants, this method can also be consid-
ered broadly representative of the UK general popula-
tions with coverage of over 11.3 million patients and 674
practices.20 An additional beneﬁt is that once partici-
pants are recruited, the anonymous data from electronic
health records (EHRs) can be linked to diverse para-
meters collected simultaneously (eg, data from air
quality monitors/mobility data) to provide detailed clin-
ical information about the study participants.
In total, 160 participants will be recruited from CPRD
using an algorithm containing validated COPD diagnos-
tic codes. Patients with data in CPRD who have a diagno-
sis of COPD based on a validated code list by Quint
et al21 are not coded for mild COPD (ie, moderate or
severe patients only), are not coded as a current smoker,
are aged >35 years, and have had between one and two
identiﬁed exacerbations in the preceding year will be
included. After running the algorithm to identify suit-
able participants, general practices that have agreed to
participate in research through CPRD will be sent a list
of the potential participants. GPs will conﬁrm to CPRD
the suitable patients identiﬁed previously using the
Vision Identiﬁcation. CPRD will then send participant
Figure 1 Project flow diagram. COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice Research Datalink; RH,
relative humidity.
Figure 2 Design of the PAM platform internals, in charging base-station and ‘en masse’. PAM, personal air monitor; RH,
relative humidity; SD, secure digital.
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information packs to the general practices to dissemin-
ate to the potential recruits. The information pack will
contain a cover letter from the general practitioner
introducing the study, a participant information sheet
with detailed information of what the project entails,
and an expression of interest form that participants can
complete and send to the research team in a prepaid
envelope. Once received, the research team will then be
able to contact the participant to enrol them in the
study through a clinic appointment. Participants will also
be recruited from respiratory clinics in secondary care as
an additional recruitment option.
The sample size of 160 patients is based on the esti-
mated number of exacerbations for the cohort. Since we
will recruit with a bias towards patients with COPD with
a history of COPD exacerbations, we have made the con-
servative estimate that we will capture at least 200 exacer-
bations with a cohort of 160 patients. We have calculated
a minimum detectable relative risk (RR) to detect asso-
ciations at p<0.05 with 80% power. With 200 exacerba-
tions, this will permit detection of about RR=1.65 in the
highest 20% of days compared with others (RR=2.00 in
the highest 10%). Other more common outcomes and
in particular peak ﬂow will have power to detect smaller
associations.22
Two secondary recruitment methods will be estab-
lished to make up any shortfall in recruits through the
CPRD: recruitment from respiratory clinics in local hos-
pitals and presentations at British Lung Foundation
‘Breathe Easy’ respiratory disease support groups.
Monitoring phase
At the clinic, participants will be provided with a PAM
and instructed to keep the monitor at home and take it
out with them for a minimum of once a week for up to
6 months. An initial questionnaire will collect informa-
tion on lifestyle factors and residence characteristics,
such as type of cooker used in the home (eg, gas, elec-
tric or wood burning stove) and car ownership. During
the study period, participants will complete daily diary
cards of their symptoms, any changes to their treatment
(eg, medications) and sleep disturbance. They will be
asked to record their peak expiratory ﬂow on the diary
card using a peak ﬂow meter. Spirometry readings will
be collected at the initial appointment and subsequent
follow-up visits if the participant consents. This will
provide information on the severity of their condition
and may control for possible random differences.
If at any stage the wearing compliance of the PAM is low,
or the participant chooses to withdraw, a replacement will
be recruited. Throughout the monitoring period, partici-
pants will receive phone calls from the research assistant to
check how they are coping with the study. Six weeks into
the monitoring period, participants will be invited to
attend a clinic with the research assistant to discuss any
Figure 3 Covariates and
comorbidities to be obtained from
EHR. COPD, chronic obstructive
pulmonary disease; CPRD,
Clinical Practice Research
Datalink; EHR, electronic health
record.
Table 1 Summary of monitored parameters of the PAMs
Parameter Method
Monitoring
interval
Spatial coordinates GPS 20 s
Background noise Microphone 100 Hz
Physical activity Triaxial
accelerometer
100 Hz
Temperature (°C) Thermocouple 20 s
RH (%) Electrical resistive
sensor
20 s
PM1, PM2.5, PM10
(μg/m3)
OPC 20 s
CO, NO, NO2, O3
(ppb)
Electrochemical
sensors
20 s
CO, carbon monoxide; GPS, Global Positioning System;
NO, nitric oxide; NO2, nitrogen dioxide; OPC, optical particle
counter; O3, ozone; PAM, personal air monitor; PM, particulate
matter; ppb, parts-per-billion; RH, relative humidity.
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issues with the PAMs or diary cards. At the end of the mon-
itoring period (at 6 months or earlier if the participant
wishes to withdraw), participants will be invited to a ﬁnal
appointment to return the PAMs and completed diary
cards.
Use of anonymised EHR from CPRD
This is a consented study and, as such, participants will
be asked to give their consent in the ﬁrst appointment
to the use of their anonymised data in the research ana-
lysis involved. CPRD will provide GOLD data sets to the
chief investigator at Imperial College London which are
then downloaded from the clinical IT system. Data will
be stored against a ‘non-identifying’ identiﬁer (ﬁrst level
anonymised) generated using a key held only by the
general practice, so that they cannot be linked back to
the data sets using Imperial College London’s online
access. A second key will be used to generate a further
level of anonymisation at the CPRD data centre before
any data are seen by researchers undertaking any aspect
of the trial analysis. In order to comply with CPRD’s
approval from the Conﬁdentiality Advisory Group of the
Health Research Authority, there will be a reidentiﬁca-
tion risk management plan in place to prevent
de-anonymising the CPRD. Since there is a way back via
the two keys to check the validity of the data, this is tech-
nically a pseudoanonymisation. At the research end,
however, patient data are effectively fully anonymised as
there is no way that a researcher can obtain access to
either of the two keys which are held securely in two dif-
ferent locations. The research assistant will only have
access to the raw patient data (collected from the daily
symptom diary cards, spirometry readings and question-
naire) and those performing the analysis will only have
access to anonymised data. All data at whatever location
will be stored in systems that fully meet all data storage
requirements and have appropriate standard operating
procedures.
Statistical associations between personal exposure with
COPD-related health outcomes
The monitoring phase of the project will create a
unique high resolution multiparameter data set of indi-
vidual exposure patterns over an extended period.
These data will be mined to explore associations
between participant’s health (symptoms, lung function
and exacerbations) and the environment through (1)
direct measurements, (2) derived variables and (3) mod-
elled outputs. Explanatory variables will include peak,
mean and cumulative exposure, rate of change, activity
level and pollutant dose/intake, lag effects, ambient pol-
lution or temperature episode effects, pollutant source
types (eg, trafﬁc, regional, domestic) and indoor/
outdoor ratios. The aim will be to identify and explain
any observed associations, allowing the translation of
results into healthcare relevant information and possible
policy updates.
Statistical analysis
Survival analyses for repeated measurements will be per-
formed on the basis of the Cox proportional hazards
model. Interval censoring for handing ties over appro-
priate event time intervals will be applied specifying
each participant to a stratum. Essentially, conditional
regression will be used to estimate the HR of subjective
health symptoms and exacerbations in relation to sea-
sonal variations of personal exposure (prognostic
factor). The conditional regression models will be devel-
oped by the PHREG procedure in SAS V.9.3 (North
Carolina, USA) with robust sandwich covariance for
aggregated data. Ties will be handled with the
DISCRETE method. Medication use will be inserted as a
control factor in the models.
Use of EHR to analyse exacerbations
CPRD GOLD data sets will be used to identify general
practitioner-treated COPD exacerbations. Information
from Hospital Episode Statistics (HES) and the Ofﬁce of
National Statistics (ONS) will also be gathered from
CPRD including: accident and emergency admissions,
hospital admissions and mortality. Mortality data from
ONS will be used as a severity index for exacerbation.
Figure 3 shows the covariates and comorbidities to be
used in the statistical analysis of COPD exacerbations.
Spatial and temporal patterns of recorded exacerba-
tions extracted from historical CPRD, HES and ONS
records will be compared with model risk estimates,
with the aim of deriving predictive algorithms for
future hospitalisations.
Activity algorithms
Time-location-activity patterns of individuals are an
important determinant of personal exposure to air pol-
lution. In this study, we will derive activity pattern com-
bining personal sensing technology with machine
learning computational techniques for automated classi-
ﬁcation and without recourse to manual activity diaries.
This method is currently being validated by the
University of Cambridge in a pilot cohort of 45 healthy
volunteers over a week as they go about their daily lives,
each of whom will keep a detailed smartphone-based
activity diary. The automated classiﬁcation of exposure
events will provide improved estimation of personal
exposure and dose which will be used to draw associa-
tions with subjective symptoms (diary cards), measured
outcomes (peak ﬂow and general practice/hospital
records from CPRD) and medication use.
Validation of the London Hybrid Exposure Model
King’s College London has previously developed a time-
activity exposure model study known as the London
Hybrid Exposure Model (LHEM),23 but full evaluation
against measured data was not possible at the time due
to limitations in mobile monitoring technology. The
extensive measurement data set gathered will primarily
provide a validation data set for the LHEM. The GPS
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coordinates collected with the PAMs, together with
the automated classiﬁcations of time-activity models
created, will be fed into the model. This will produce a
modelled time-series exposure estimate for each pollu-
tant. These estimates will be compared with measured
pollutant exposure and performance for targeted pol-
lutants in different microenvironments, with the aim
of deriving uncertainty estimates for future model
applications. Calibrated model results will be com-
pared with static exposure estimate methodologies,
such as central monitor or postcode, to quantify the
exposure misclassiﬁcation associated with each. The
integrated data set collected during the monitoring
phase will also provide the opportunity to verify and
reﬁne model inﬁltration factors for indoor and trans-
port microenvironments, incorporating emissions from
indoor sources and human activities, such as cooking
and smoking.
This combined monitoring–modelling methodology
for time-activity exposure model development and evalu-
ation will be applicable to a wide range of cohort and
epidemiological studies investigating links between envir-
onmental exposure and diverse health outcomes.
Development of a COPD prediction model
Associations between exacerbations with spatiotempor-
ally resolved environmental exposure established in the
Statistical associations between personal exposure with
COPD-related health outcomes section will be combined
with the time-activity exposure model (LHEM) to create
a predictive model for COPD exacerbations across
London. First, time-location-activity patterns of the
COPD cohort will be compared with general population-
level time-activity patterns derived from the Trafﬁc
Pollution and Health in London project.24 This will be
used to test the applicability of general population
behaviour patterns when assessing COPD associations in
epidemiological studies.
The association between personal exposure to air pol-
lution with COPD exacerbations estimated in the
Statistical associations between personal exposure with
COPD-related health outcomes section will form the
basis of the COPD prediction model. This model will be
used to create high resolution (20×20 m grid) daily
COPD exacerbation risk maps for the years 2005–2011,
based on modelled meteorological and pollutant condi-
tions, coupled with typical patient with COPD time-
activity patterns identiﬁed in the Activity algorithms
section. The model will thus retrospectively predict days
and locations more likely to trigger a worsening of symp-
toms and/or exacerbation in patients with COPD over
this time period.
The performance of the predictive model will be eval-
uated using validated methods for patient identiﬁca-
tion21 from EHRs, CPRD, HES and ONS death data
excluding data from the COPE cohort. Spatial and tem-
poral patterns of recorded exacerbations will be com-
pared with model risk estimates linked to the home
address. If it is demonstrated that there are signiﬁcant
associations between model predictions and recorded
exacerbations, the algorithms used will be generalised
for use outside of London. These algorithms will
provide an opportunity for the development of a
national COPD forecasting service with proven perform-
ance in predicting increased risk of exacerbations.
DISCUSSION
Several studies have attempted to identify relationships
between environmental factors and COPD exacerba-
tions.25 26 However, limitations of the methodological
design of previous studies have made it difﬁcult to iden-
tify clear links between exposure and health outcomes.
The strength of this study lies in the fact that we will
have the ability to assess these associations in far more
detail, initially at the individual patient level and poten-
tially at a national level.
For the ﬁrst time, this study will provide a multidiscip-
linary methodological framework that will bring
together recent advancements in low-cost wearable
sensors, computational techniques for the estimation of
activity-weighted personal exposure and advanced spatial
mapping in a well-characterised population study. The
integrated database of environmental stressors and activ-
ity patterns at the individual level will form the basis for
the validation of the LHEM. The LHEM can further
incorporate spatial and temporal patterns of recorded
exacerbations extracted from historical CPRD, HES and
ONS records to form a COPD prediction model for
future hospitalisations.
Limitations include the fact that participants will be
asked to participate in the study for up to 6 months in
order to try and capture seasonal changes in exacerba-
tions and some may be dissuaded by this. Despite the
process of identifying and recruiting patients via CPRD,
there may be insufﬁcient numbers of patients who are
interested in participating to power the study. Owing to
these recruitment concerns, we are not planning to
request blood and sputum samples from all participants,
and this means that we will not have any biological data
from some participants to assess physiological and
inﬂammatory changes during their exacerbations.
However, funding has been obtained for a substudy
within COPE to collect blood and sputum samples in a
subset of 20 participants at baseline, exacerbation and
4 weeks post exacerbation.
The methodology presented here will allow develop-
ment of forecasting models that can be used to predict
times of increased exacerbation risk. This will aid health-
care providers and allow more accurate planning and
allocation of resources which will reduce costs for the
NHS. It will aid patients as it may provide an opportunity
to alter behaviour and to prevent exacerbations from
occurring. By providing a more robust evidence base,
policymakers may be able to take more targeted and efﬁ-
cient decisions on reducing environmental risk.
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Members of the public will be able to make more
informed decisions on how to minimise their own risks,
improving health and quality of life.
ETHICS AND DISSEMINATION
CPRD has been granted Multiple Research Ethics
Committee (MREC) approval to undertake observa-
tional studies and external data linkages with HES and
ONS. Research and Development (R&D) approval has
also been granted by the Royal Brompton and Hareﬁeld
NHS Foundation Trust and Guy’s and St Thomas’ NHS
Foundation Trust to carry out the study at the Clinical
Research Facility in the Royal Brompton Hospital and
the Lane Fox Respiratory Unit at St Thomas’ Hospital
(IRAS ref 166785). Ethical approval is being sought to
collect blood and sputum samples from a subset of 20
participants for a pilot study.
Participants will be informed that the monitors use
GPS technology and will provide spatial data at intervals
during the day. Participants will be reassured that this
information will only be accessed at the end of the study
to analyse overall spatial and temporal relationships and
not real-time movement. In addition, participants will be
informed that the monitors will have a built-in micro-
phone for the purpose of recording ambient (back-
ground) noise levels. It will not be used for the
recording of speech.
The behavioural and environmental COPD associa-
tions identiﬁed during the study will be adapted for
application on a national scale and disseminated to
healthcare providers including the Department of
Health, Clinical Commissioning Groups and GPs.
Information will include evidence of environmental con-
ditions and patient activities that are found to contribute
to an increased risk of COPD symptoms and exacerba-
tions. The predictive algorithms will be made available,
allowing the development of a validated national COPD
forecasting system. Such a system has the potential for
further commercial exploitation and the research team
will seek to collaborate with the UK Meteorological
Ofﬁce in order to improve the effectiveness of their
Healthy Outlook service. This research would provide
an opportunity to carry out a cost–beneﬁt analysis of
such a system, now essential for commissioning in the
current health market.
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